Checkpoint Inhibitors Global Market Report 2024

Description

Checkpoint inhibitors represent a form of immunotherapy that disrupts the interaction between immune checkpoint proteins, enabling T cells to combat cancer cells by avoiding the suppression signal. Among these medications, one targets the checkpoint protein CTLA-4.

Within the realm of checkpoint inhibitors, the primary drug categories include PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, chimeric antigen receptor T-cells (CAR-T), and other variants. PD-1 and PD-L1 inhibitors specifically hinder the function of immune checkpoint proteins present on cell surfaces, aiding in the treatment of conditions like lung cancer, renal cancer, blood cancer, bladder cancer, melanoma, and more. These therapies find application across diverse sectors encompassing hospital pharmacies, retail pharmacies, and online pharmacy services.

The checkpoint inhibitors market research report is one of a series of new reports from The Business Research Company that provides checkpoint inhibitors market statistics, including checkpoint inhibitors industry global market size, regional shares, competitors with a checkpoint inhibitors market share, detailed checkpoint inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the checkpoint inhibitors industry. This checkpoint inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The checkpoint inhibitors market size has grown rapidly in recent years. It will grow from $32.41 billion in 2023 to $37.88 billion in 2024 at a compound annual growth rate (CAGR) of 16.9%. The growth observed in the historical period can be attributed to several factors, including the escalating incidence of cancer cases, heightened awareness surrounding checkpoint inhibitors, the broadening spectrum of approved checkpoint inhibitors, active research and development endeavors focused on novel checkpoint inhibitors, and the proliferation of clinical trials and extensive research in this field.

The checkpoint inhibitors market size is expected to see rapidly grown in the next few years. It will grow to $55.64 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%. Anticipated growth in the forecast period is expected to stem from several factors, notably the expansion of indications for checkpoint inhibitors, ongoing discoveries in biomarkers, the evolution of combination therapies, the increasing focus on personalized medicine, and the continued broadening of indications.

The surge in global cancer cases is poised to drive the checkpoint inhibitors market, buoyed by a projected increase in new diagnoses and cancer-related deaths, as highlighted by the American Cancer Society in January 2022. With prevalent cancers like lung, prostate, bowel, and female breast cancer constituting a significant percentage of new cases, the efficacy of checkpoint inhibitors targeting these checkpoints stands pivotal in cancer therapy. The market for these inhibitors is expected to surge in response to the escalating rates of cancer incidence worldwide.

The checkpoint inhibitors market is set to expand further, propelled by a concurrent rise in healthcare expenditure. This expenditure encompasses a spectrum of activities, from drug development to patient access and support. Notably, the Office for National Statistics reported a substantial increase in healthcare spending in the UK between 2020 and 2021, reflecting a heightened investment in pharmaceuticals and preventive care. Such augmented healthcare expenditure is a key driver behind the growth of the checkpoint inhibitors market.

Major players in the checkpoint inhibitor realm are forging strategic partnerships to advance technologies like bifunctional fusion proteins or Y-trap, aiming to enhance the efficacy of immunotherapies. In June 2021, Merck and GSK's global strategic partnership to develop and market M7824 (bintrafusp alfa), an investigational bi-functional fusion protein immunotherapy, exemplifies this trend. Similarly, collaborations like GSK's alliance with ITeos Therapeutics seek to leverage expertise in immuno-oncology to expedite the development and commercialization of innovative therapies such as EOS-448.

Keytruda (pembrolizumab), an immunotherapy drug categorized as a checkpoint inhibitor, exemplifies the innovation in the checkpoint inhibitors market. Merck & Co., Inc. obtained FDA approval in March 2022 for Keytruda to treat patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial carcinoma. Keytruda's mechanism involves enabling the immune system to identify and combat cancer cells by blocking checkpoint proteins, offering an effective treatment avenue either individually or in combination with other cancer therapies.

In November 2021, Pfizer Inc., a US-based pharmaceutical industry company, acquired Trillium Therapeutics Inc. for $2.22 billion. Through this acquisition, Pfizer aims to strengthen its oncology portfolio with the addition of next-generation investigational immunotherapeutics for hematological malignancies and gain access to Trillium's two lead molecules. Trillium Therapeutics Inc. is a US-based biotech company developing innovative checkpoint inhibitors for the treatment of cancer.

Major companies operating in the checkpoint inhibitors market include AstraZeneca PLC, Bristol-Myers Squibb Company, Merck & Co. Inc., Roche Holding AG, Pfizer Inc., Incyte Corporation, Novartis AG, NewLink Genetics Corporation, Seattle Genetics Inc., Celldex Therapeutics, GlaxoSmithKline PLC, Innate Pharma S.A., Ono Pharmaceutical Co. Ltd., Juno Therapeutics, Kite Pharma, Eli Lilly and Company (ARMO Biosciences.), Fortress Biotech, Argenx SE, MacroGenics, CureTech, Sorrento Therapeutics, Sanofi S.A, F. Hoffmann-La Roche Ltd., AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Celgene Corporation, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Kyowa Kirin Co. Ltd., Johnson & Johnson, Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Y-mAbs Therapeutics Inc., Zai Lab Limited

North America was the largest region in the checkpoint inhibitors market in 2023. The Middle East is expected to be the fastest growing region in the global checkpoint inhibitors market share during the forecast period. The regions covered in the checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the checkpoint inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The checkpoint inhibitors market consists of sales of atezolizumab, avelumab, and durvalumab. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Checkpoint Inhibitors Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on checkpoint inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for checkpoint inhibitors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The checkpoint inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Drug: PD-1 Inhibitors; PD-L1 Inhibitors; CTLA-4; Chimeric Antigen Receptor T-cell; Other Drugs
2) By Application: Lung Cancer; Renal Cancer; Blood Cancer; Bladder Cancer; Melanoma; Other Applications
3) By End-Users: Hospitals Pharmacies; Retail Pharmacies; Online Pharmacies
Companies Mentioned: AstraZeneca plc; Bristol-Myers Squibb Company; Merck & Co. Inc.; Roche Holding AG; Pfizer Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r13208

1. Executive Summary

2. Checkpoint Inhibitors Market Characteristics

3. Checkpoint Inhibitors Market Trends And Strategies

4. Checkpoint Inhibitors Market - Macro Economic Scenario

4.1. Impact Of High Inflation On the Market
4.2. Ukraine-Russia War Impact On the Market
4.3. COVID-19 Impact On the Market

5. Global Checkpoint Inhibitors Market Size and Growth

5.1. Global Checkpoint Inhibitors Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Checkpoint Inhibitors Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Checkpoint Inhibitors Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Checkpoint Inhibitors Market Segmentation

6.1. Global Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4
Chimeric Antigen Receptor T-cell
Other Drugs
6.2. Global Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Lung Cancer
Renal Cancer
Blood Cancer
Bladder Cancer
Melanoma
Other Applications
6.3. Global Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies

7. Checkpoint Inhibitors Market Regional And Country Analysis

7.1. Global Checkpoint Inhibitors Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Checkpoint Inhibitors Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Checkpoint Inhibitors Market

8.1. Asia-Pacific Checkpoint Inhibitors Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Checkpoint Inhibitors Market

9.1. China Checkpoint Inhibitors Market Overview
9.2. China Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Checkpoint Inhibitors Market

10.1. India Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Checkpoint Inhibitors Market

11.1. Japan Checkpoint Inhibitors Market Overview
11.2. Japan Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Checkpoint Inhibitors Market

12.1. Australia Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Checkpoint Inhibitors Market

13.1. Indonesia Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Checkpoint Inhibitors Market

14.1. South Korea Checkpoint Inhibitors Market Overview
14.2. South Korea Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Checkpoint Inhibitors Market

15.1. Western Europe Checkpoint Inhibitors Market Overview
15.2. Western Europe Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Checkpoint Inhibitors Market

16.1. UK Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Checkpoint Inhibitors Market

17.1. Germany Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Checkpoint Inhibitors Market

18.1. France Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Checkpoint Inhibitors Market

19.1. Italy Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Checkpoint Inhibitors Market

20.1. Spain Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Checkpoint Inhibitors Market

21.1. Eastern Europe Checkpoint Inhibitors Market Overview
21.2. Eastern Europe Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Checkpoint Inhibitors Market

22.1. Russia Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Checkpoint Inhibitors Market

23.1. North America Checkpoint Inhibitors Market Overview
23.2. North America Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Checkpoint Inhibitors Market

24.1. USA Checkpoint Inhibitors Market Overview
24.2. USA Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Checkpoint Inhibitors Market

25.1. Canada Checkpoint Inhibitors Market Overview
25.2. Canada Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Checkpoint Inhibitors Market

26.1. South America Checkpoint Inhibitors Market Overview
26.2. South America Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Checkpoint Inhibitors Market

27.1. Brazil Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Checkpoint Inhibitors Market

28.1. Middle East Checkpoint Inhibitors Market Overview
28.2. Middle East Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Checkpoint Inhibitors Market

29.1. Africa Checkpoint Inhibitors Market Overview
29.2. Africa Checkpoint Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Checkpoint Inhibitors Market Competitive Landscape And Company Profiles

30.1. Checkpoint Inhibitors Market Competitive Landscape
30.2. Checkpoint Inhibitors Market Company Profiles
- 30.2.1. AstraZeneca plc
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. Bristol-Myers Squibb Company
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. Merck & Co. Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Roche Holding AG
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Pfizer Inc
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Global Checkpoint Inhibitors Market Competitive Benchmarking

32. Global Checkpoint Inhibitors Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Checkpoint Inhibitors Market

34. Checkpoint Inhibitors Market Future Outlook and Potential Analysis

34.1 Checkpoint Inhibitors Market In 2028 - Countries Offering Most New Opportunities
34.2 Checkpoint Inhibitors Market In 2028 - Segments Offering Most New Opportunities
34.3 Checkpoint Inhibitors Market In 2028 - Growth Strategies
- 34.3.1 Market Trend Based Strategies
- 34.3.2 Competitor Strategies

35. Appendix

35.1. Abbreviations
35.2. Currencies
35.3. Historic And Forecast Inflation Rates
35.4. Research Inquiries
35.5. The Business Research Company
35.6. Copyright And Disclaimer